7,8-Dihydroxyflavone ameliorates mitochondrial impairment and motor dysfunction in the ?-synuclein 1-103 transgenic mice

Ye Tian,Lina Pan,Xin Yuan,Min Xiong,Zhaohui Zhang,Lanxia Meng,Yongfa Zheng,Lihong Bu,Ximing Xu,Zhentao Zhang

DOI: https://doi.org/10.1016/j.nbd.2022.105736

IF: 7.046

2022-01-01

Neurobiology of Disease

Abstract:Parkinson's disease (PD) is the most common motor-associated neurodegenerative disease. Although the path-ogenesis of PD is still wrapped in the mist, accumulating evidence indicates that mitochondrial dysfunction contributes to the onset and progression of PD. We previously reported that the lysosomal protease asparagine endopeptidase (AEP) cleaves alpha-synuclein in the brains of PD patients. The major product, alpha-synuclein 1-103, significantly promotes PD-like histological changes and motor dysfunction. However, the underlying molecular mechanisms remain unknown. Here we show that alpha-synuclein 1-103 fragment interacts with mitochondria and induces morphological and functional abnormalities of mitochondria. Furthermore, we investigated the pro-tective effects of 7,8-dihydroxyflavone (7,8-DHF) on mitochondrial dysfunction induced by alpha-synuclein 1-103 fragment. We found that 7,8-DHF ameliorated alpha-synuclein 1-103-induced mitochondrial impairment and motor dysfunction. These results indicate that 7,8-DHF represents a novel oral bioactive therapeutic agent for treating PD.